U.S. Markets closed

Merck & Co., Inc. (MRK)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
62.94+0.32 (+0.51%)
At close: 4:00PM EDT

63.18 0.24 (0.39%)
After hours: 5:26PM EDT

People also watch
PFEJNJBMYLLYPG
Full screen
Previous Close62.62
Open62.91
Bid62.30 x 300
Ask63.18 x 100
Day's Range62.85 - 63.24
52 Week Range57.18 - 66.80
Volume6,593,696
Avg. Volume8,935,647
Market Cap172.15B
Beta0.97
PE Ratio (TTM)40.11
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.88 (3.01%)
Ex-Dividend Date2017-06-13
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters5 hours ago

    FDA tentatively approves Merck's copycat of Sanofi's Lantus

    Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its biosimilar version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus. Merck's copycat, if launched, would challenge Lantus as a cheaper alternative that could chip away at the drug's sales, which reached 5.71 billion euros ($6.6 billion) last year and represented over a sixth of Sanofi's total sales.

  • Market Realistyesterday

    How Merck’s Isentress Is Expected to Perform in 2017

    In 2016, Merck’s (MRK) Isentress reported revenues of ~$1.4 billion, which reflected an ~8% decline year-over-year.

  • Market Realist2 days ago

    Merck’s Diabetes Franchise Could Generate Steady Revenues in 2017

    In 2016, Merck’s Janumet (sitagliptin and metformin HCl) reported revenues of around $2.2 billion, which reflected ~2% YoY growth.